Author | Lois Wingerson

April 27, 2011

There's reason to question whether lenalidomide is the cause of secondary cancers in patients who take it as an adjuvant. But new scrutiny may help to clarify how it acts against the primary.

March 31, 2011

An ethnographic study of palliative care specialists reveals that many of them find dealing with dying patients a gratifying experience. The scant evidence about oncologists on this subject paints a much different picture.

March 16, 2011

P13K inhibitors, now in the earliest stages of clinical testing, receive hopeful attention as an alternative for patients with aromatase inhibitor resistance. A new study proposes how they should be used, and for whom.

February 17, 2011

Patients with advanced melanoma now have access to the BRAF inhibitor PLX4032, which has shown survival advantages in a Phase III trial, as long as they have the "right" mutation. The drug's history so far is proving a case study on the challenges of developing personalized cancer treatment.